BlueWind Medical Secures $47.8 Million in Financing

BlueWind Medical Ltd. has closed $47.8 million in financing through a combination of equity and debt. The money will go toward commercialization efforts for the Revi System, a patient-centric solution for urgency urinary incontinence (UUI).

BlueWind Medical also will use the funding to expand the company’s commercial sales organization and ongoing investment in market access initiatives that broaden patient and provider access to the therapy.

“Urgency urinary incontinence affects millions of people, creating a significant need for effective, durable treatment options that fit seamlessly into patients’ lives,” BlueWind Medical CEO Kerry Nelson said. “This financing reflects deep conviction in our team, our technology, and the opportunity ahead to establish Revi as the new standard of care.”

The financing builds on a series of clinical achievements over the past year, including three-year results from the pivotal OASIS study that confirmed Revi’s sustained efficacy, excellent safety, and 95% patient satisfaction at 36 months.¹

Revi is an implantable tibial neuromodulation (ITNM) device designed to treat UUI. Implanted near the ankle in a single outpatient procedure under local anesthesia, Revi delivers targeted stimulation to the posterior tibial nerve through a lightweight, external wearable. This design offers patients a simple, durable, and effective long-term solution for UUI symptom relief, according to the company. Patients activate therapy once daily at home, without the need for internal batteries or leads, avoiding complications such as lead fracture, migration, or battery depletion.

“This financing is an important milestone for BlueWind and a strong validation of the progress we are making as a leader in Implantable Tibial Neuromodulation for urgency urinary incontinence,” BlueWind Medical Chief Financial Officer Stephen Armstrong stated. “The capital allows us to scale our commercial organization, expand market access, and ensure that more patients and providers can benefit from a clinically proven, patient-centric therapy. We are grateful for the continued confidence of our investors as we execute on the next phase of our growth.”

BlueWind Medical develops patient-centric medical technology for disease treatment. Its Revi System is the first and only Implantable ITNM device activated by a battery-operated external wearable to receive U.S. Food and Drug Administration clearance for UUI treatment.

Reference
1 Amundsen CL, Sutherland SE, Heesakkers JPFA, Toozs-Hobson P, Martens F, McCrery RJ, et al. Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation from the Pivotal OASIS Study. Journal of Urology. 2026 April; 0(0): https://doi.org/10.1097/JU.0000000000005062